Navigation Links
PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
Date:6/2/2009

ANNAPOLIS, Md., June 2 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has submitted a proposal to the Biomedical Advanced Research and Development Authority (BARDA) in response to a Broad Agency Announcement (BAA-BARDA-09-34) for advanced research and development of medical countermeasures for chemical, biological, radiological and nuclear threats. PharmAthene has requested funding to further develop Valortim(R), a fully human monoclonal antibody, for the prevention and treatment of anthrax infection. To date, the Company has received funding commitments from the U. S. government totaling up to $24 million to advance the development of Valortim(R).

David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "We look forward to BARDA's decision regarding our funding proposal for the advanced development of Valortim(R). We believe that Valortim(R) may have important competitive advantages, including a novel mechanism of action, which, if demonstrated, would make it a strong choice for procurement consideration in the Strategic National Stockpile (SNS). Additional funding will allow us to complete clinical and non-clinical efforts through pivotal safety and efficacy studies, and to perform cGMP and conformance lot manufacturing. If successful, Valortim(R) may be eligible for acquisition into the SNS for potential use under an Emergency Use Authorization (EUA), and for submission of a Biologics License Application (BLA)."

About Valortim(R)

Valortim(R) is a fully human monoclonal antibody generated by Medarex, Inc's UltiMAb(R) technology that is being co-developed by the two companies and is designed to protect against and treat anthrax infection, including inhala
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
2. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
3. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
4. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
5. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
6. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
7. Human Genome Sciences Submits Biologics License Application to FDA for ABthrax(TM)
8. Cadence Pharmaceuticals Submits Acetavance New Drug Application for the Treatment of Acute Pain and Fever
9. D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
10. AstraZeneca Submits NDA for Low Dose Aspirin/Esomeprazole Combination Product
11. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/1/2014)... companies EBI, LLC, of New Jersey , and ... pay the United States $6.07 million to ... the companies, bone growth stimulators. The settlement this week ... Biomet, Yue Yu, pursuant to the qui tam provisions ... , LLP, a Philadelphia -based personal injury law ...
(Date:11/1/2014)... Wash. , Oct. 31, 2014 Talyst, ... at the 2014 American Society of Consultant Pharmacists (ASCP) ... The meeting and expo will bring together pharmacists and ... the latest technologies. In recent years, ... focus for LTC pharmacies. The InSite® System, Talyst,s LTC ...
(Date:11/1/2014)... and CHICAGO , Oct. 31, 2014 ... Durata Therapeutics, Inc. (NASDAQ: DRTX ) today ... granted early termination of the waiting period under the ... to Actavis, pending acquisition of Durata. Logo ... termination of the HSR waiting period satisfies one of ...
Breaking Medicine Technology:Biomet to Pay Over $6 Million to Resolve Whistleblower Claims That It Paid Kickbacks to Doctors 2Talyst Exhibits at ASCP Annual Meeting 2Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 2Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 3Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 5Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 6
... 2011 As part of a nationwide effort to prevent ... supporting National Prescription Drug Take-Back Day, which is ... on Saturday, October 29. "Unused prescription medicines that ... are not handled properly," said Paul Kaplan, M.D., BCBSD Vice ...
... information from a recent proprietary study affirming that seeing is ... seeing was an overwhelming choice, selected by 10 times as ... "This research affirms how important seeing is to people and ... VisionSpring President. "With over 700 million people in the world ...
Cached Medicine Technology:Blue Cross Blue Shield of Delaware Supports the Drug Enforcement Administration's "National Prescription Drug Take-Back Day" 2VisionSpring Research Finds Seeing to be the Most Important of Five Senses 2
(Date:10/31/2014)... (PRWEB) October 31, 2014 Springboard ... for its small scale BioPro™ biodiesel processors, announced ... will further improve the performance and efficiency of ... GL95/MC12/BD380 trio will recover more than ... in with the glycerin by-product produced while making ...
(Date:10/31/2014)... October 31, 2014 The Memory Healer review ... by Alexander Lynch, whose father suffered from Alzheimer's disease. ... moment, caused by his father's disease. His father pointed a ... the crucial moment when the author of this method understood ... , The Memory Healer program is based on years ...
(Date:10/31/2014)... October 31, 2014 At the start ... families narrowly escaping carbon monoxide poisoning in their homes. ... weeks away, one family-owned, Missouri-based heating and cooling company ... making sure families start the home heating season with ... secure. , Beginning Nov. 1, 2014, E and ...
(Date:10/31/2014)... Surgery for low back pain caused by spinal stenosis ... live, a new report says. "Nearly 80 percent ... point in their lives, and about 30 million people ... problem," co-author Brook Martin, of the Dartmouth Institute of ... news release. In spinal stenosis, thickening of tissue ...
(Date:10/31/2014)... research suggests that insomnia is a major contributor to ... fatal injuries. The results underscore the importance of the ... Sleep Awareness Project. , Results show that the risk ... with the number of insomnia symptoms present. People with ... likely to die from a fatal injury than those ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... , ... ... , , , , ... ...
... A surge in volunteers following a major ... coordination, can actually make a situation worse instead of ... the devastating earthquake that rocked Haiti in January provides ... say the authors of a New England Journal ...
... ... in Direct Selling Industry With the Promotion of the First EcoAdvisor to Achieve EcoDirector ... ... one of its founding EcoAdvisors has reached the highest level of achievement, EcoDirector status. ...
... ... unrecognized set of targets and biomarkers to battle solid tumors. , ... (Vocus) February 24, 2010 -- Cancer researchers ... battle solid tumors. , , , , ,The findings center on discovery of signaling ...
... ... ... ... ...
... , ... ... ... ...
Cached Medicine News:Health News:Pelosi on Repealing Antitrust Exemption: Health Insurance Companies Will Now Be Playing on the People's Field 2Health News:Pelosi on Repealing Antitrust Exemption: Health Insurance Companies Will Now Be Playing on the People's Field 3Health News:Pelosi on Repealing Antitrust Exemption: Health Insurance Companies Will Now Be Playing on the People's Field 4Health News:Pelosi on Repealing Antitrust Exemption: Health Insurance Companies Will Now Be Playing on the People's Field 5Health News:Health care volunteers and disasters: First, be prepared 2Health News:OnlyGreen Celebrates First EcoDirector 2Health News:New Cancer-Fighting Strategy Focuses On Signaling Molecules 2Health News:New Cancer-Fighting Strategy Focuses On Signaling Molecules 3Health News:U.S. Senate Urgently Needs to Extend 'Medicaid Match' in Economic Recovery Legislation 2Health News:U.S. Senate Urgently Needs to Extend 'Medicaid Match' in Economic Recovery Legislation 3Health News:U.S. Senate Urgently Needs to Extend 'Medicaid Match' in Economic Recovery Legislation 4Health News:U.S. Senate Urgently Needs to Extend 'Medicaid Match' in Economic Recovery Legislation 5Health News:Express Scripts Reports Strong Fourth Quarter Earnings 2Health News:Express Scripts Reports Strong Fourth Quarter Earnings 3Health News:Express Scripts Reports Strong Fourth Quarter Earnings 4Health News:Express Scripts Reports Strong Fourth Quarter Earnings 5Health News:Express Scripts Reports Strong Fourth Quarter Earnings 6Health News:Express Scripts Reports Strong Fourth Quarter Earnings 7Health News:Express Scripts Reports Strong Fourth Quarter Earnings 8Health News:Express Scripts Reports Strong Fourth Quarter Earnings 9Health News:Express Scripts Reports Strong Fourth Quarter Earnings 10Health News:Express Scripts Reports Strong Fourth Quarter Earnings 11Health News:Express Scripts Reports Strong Fourth Quarter Earnings 12Health News:Express Scripts Reports Strong Fourth Quarter Earnings 13Health News:Express Scripts Reports Strong Fourth Quarter Earnings 14Health News:Express Scripts Reports Strong Fourth Quarter Earnings 15Health News:Express Scripts Reports Strong Fourth Quarter Earnings 16Health News:Express Scripts Reports Strong Fourth Quarter Earnings 17Health News:Express Scripts Reports Strong Fourth Quarter Earnings 18Health News:Express Scripts Reports Strong Fourth Quarter Earnings 19Health News:Express Scripts Reports Strong Fourth Quarter Earnings 20Health News:Express Scripts Reports Strong Fourth Quarter Earnings 21Health News:Express Scripts Reports Strong Fourth Quarter Earnings 22
Acuvue Toric is an exceptionally comfortable soft contact lens made especially for people with astigmatism. The Acuvue Toric lens is designed to comfortably fit the unique shape of your eye....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
... Vitrasert implant is a device that ... Aids-related Cytomegalovirus (CMV) Retinitis. This approach ... when compared with conventional intravenous treatment. ... in a polymer-based system that slowly ...
Near PT test card/illus of the ocular adnexa 5 1/2" X 8"....
Medicine Products: